{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:39:45Z","timestamp":1792571985207,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Longyan City Science and Technology Plan Project","award":["2023LYF17030"],"award-info":[{"award-number":["2023LYF17030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05732-6","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:57:42Z","timestamp":1790157462000},"page":"5605-5620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["METTL3\u2011mediated OTUB1 sustains PD\u2011L1 protein stability via deubiquitination and promotes immune evasion in oral squamous cell carcinoma"],"prefix":"10.1007","volume":"481","author":[{"given":"Dongbin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juncai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"5732_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105451","volume":"121","author":"A Chamoli","year":"2021","unstructured":"Chamoli A, Gosavi AS, Shirwadkar UP et al (2021) Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics. Oral Oncol 121:105451","journal-title":"Oral Oncol"},{"key":"5732_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155489","volume":"261","author":"D Jagadeesan","year":"2024","unstructured":"Jagadeesan D, Sathasivam KV, Fuloria NK et al (2024) Comprehensive insights into oral squamous cell carcinoma: diagnosis, pathogenesis, and therapeutic advances. Pathol Res Pract 261:155489","journal-title":"Pathol Res Pract"},{"key":"5732_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20032392","author":"G Feller","year":"2023","unstructured":"Feller G, Khammissa RAG, Ballyram R et al (2023) Tumour genetic heterogeneity in relation to oral squamous cell carcinoma and anti-cancer treatment. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph20032392","journal-title":"Int J Environ Res Public Health"},{"key":"5732_CR4","doi-asserted-by":"publisher","first-page":"629888","DOI":"10.3389\/fmolb.2021.629888","volume":"8","author":"ZJ Law","year":"2021","unstructured":"Law ZJ, Khoo XH, Lim PT et al (2021) Extracellular vesicle-mediated chemoresistance in oral squamous cell carcinoma. Front Mol Biosci 8:629888","journal-title":"Front Mol Biosci"},{"key":"5732_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/v13071234","author":"PL Stern","year":"2021","unstructured":"Stern PL, Dalianis T (2021) Oropharyngeal squamous cell carcinoma treatment in the era of immune checkpoint inhibitors. Viruses. https:\/\/doi.org\/10.3390\/v13071234","journal-title":"Viruses"},{"issue":"1","key":"5732_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12672-025-01997-3","volume":"16","author":"L He","year":"2025","unstructured":"He L, Wan M, Yang X et al (2025) Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment. Discov Oncol 16(1):257","journal-title":"Discov Oncol"},{"issue":"3","key":"5732_CR7","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3390\/cimb46030136","volume":"46","author":"X Xi","year":"2024","unstructured":"Xi X, Zhao W (2024) Anti-tumor potential of post-translational modifications of PD-1. Curr Issues Mol Biol 46(3):2119\u20132132","journal-title":"Curr Issues Mol Biol"},{"key":"5732_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117348","volume":"179","author":"Y Wu","year":"2024","unstructured":"Wu Y, Mohd Sani SB, Peng K et al (2024) Research progress of the otubains subfamily in hepatocellular carcinoma. Biomed Pharmacother 179:117348","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5732_CR9","doi-asserted-by":"publisher","first-page":"9106","DOI":"10.1080\/21655979.2022.2057897","volume":"13","author":"D Ye","year":"2022","unstructured":"Ye D, Wang S, Wang X et al (2022) Overexpression of OTU domain-containing ubiquitin aldehyde-binding protein 1 exacerbates colorectal cancer malignancy by inhibiting protein degradation of beta-Catenin via Ubiquitin-proteasome pathway. Bioengineered 13(4):9106\u20139116","journal-title":"Bioengineered"},{"issue":"9","key":"5732_CR10","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/s41418-022-00971-8","volume":"29","author":"X Han","year":"2022","unstructured":"Han X, Ren C, Lu C et al (2022) Deubiquitination of MYC by OTUB1 contributes to HK2 mediated glycolysis and breast tumorigenesis. Cell Death Differ 29(9):1864\u20131873","journal-title":"Cell Death Differ"},{"issue":"6","key":"5732_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41418-020-00700-z","volume":"28","author":"D Zhu","year":"2021","unstructured":"Zhu D, Xu R, Huang X et al (2021) Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ 28(6):1773\u20131789","journal-title":"Cell Death Differ"},{"issue":"6","key":"5732_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.molmed.2023.03.005","volume":"29","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang D, Liu T et al (2023) N6-methyladenosine-mediated gene regulation and therapeutic implications. Trends Mol Med 29(6):454\u2013467","journal-title":"Trends Mol Med"},{"issue":"1","key":"5732_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12943-022-01508-w","volume":"21","author":"L Liu","year":"2022","unstructured":"Liu L, Li H, Hu D et al (2022) Insights into N6-methyladenosine and programmed cell death in cancer. Mol Cancer 21(1):32","journal-title":"Mol Cancer"},{"issue":"1","key":"5732_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-021-01129-8","volume":"14","author":"W Huang","year":"2021","unstructured":"Huang W, Chen TQ, Fang K et al (2021) N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol 14(1):117","journal-title":"J Hematol Oncol"},{"issue":"2","key":"5732_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/odi.14016","volume":"29","author":"T Xu","year":"2023","unstructured":"Xu T, Zhang W, Chai L et al (2023) Methyltransferase-like 3-induced N6-methyladenosine upregulation promotes oral squamous cell carcinoma by through p38. Oral Dis 29(2):639\u2013648","journal-title":"Oral Dis"},{"issue":"10","key":"5732_CR16","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","volume":"30","author":"Z Kuang","year":"2023","unstructured":"Kuang Z, Liu X, Zhang N et al (2023) USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1. Cell Death Differ 30(10):2249\u20132264","journal-title":"Cell Death Differ"},{"issue":"1","key":"5732_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-022-01705-7","volume":"21","author":"J Wang","year":"2022","unstructured":"Wang J, Tan L, Yu X et al (2022) lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942\/TNS1 axis and is positively regulated by the m(6)A reader YTHDC2. Mol Cancer 21(1):229","journal-title":"Mol Cancer"},{"issue":"3","key":"5732_CR18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.62347\/JMFF8182","volume":"14","author":"Q Wu","year":"2024","unstructured":"Wu Q, Liu R, Yang Y et al (2024) USP5 promotes tumorigenesis by activating Hedgehog\/Gli1 signaling pathway in osteosarcoma. Am J Cancer Res 14(3):1204\u20131216","journal-title":"Am J Cancer Res"},{"issue":"7","key":"5732_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41590-019-0405-2","volume":"20","author":"X Zhou","year":"2019","unstructured":"Zhou X, Yu J, Cheng X et al (2019) The deubiquitinase Otub1 controls the activation of CD8(+) T cells and NK cells by regulating IL-15-mediated priming. Nat Immunol 20(7):879\u2013889","journal-title":"Nat Immunol"},{"issue":"328","key":"5732_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv4","journal-title":"Sci Transl Med"},{"issue":"3","key":"5732_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW et al (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76(3):359\u2013370","journal-title":"Mol Cell"},{"issue":"9","key":"5732_CR22","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.7150\/ijbs.69771","volume":"18","author":"J Chen","year":"2022","unstructured":"Chen J, Fang Y, Xu Y et al (2022) Role of m6A modification in female infertility and reproductive system diseases. Int J Biol Sci 18(9):3592\u20133604","journal-title":"Int J Biol Sci"},{"issue":"6","key":"5732_CR23","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.62347\/HERV8396","volume":"15","author":"C Chen","year":"2025","unstructured":"Chen C, Li J, Yang B et al (2025) METTL3-mediated m(6)A methylation of lncRNA PVT1 promotes the progression of oral squamous cell carcinoma via the miR-185-5p\/SERPINB4 axis. Am J Cancer Res 15(6):2872\u20132889","journal-title":"Am J Cancer Res"},{"issue":"12","key":"5732_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306515","volume":"11","author":"Y Zhi","year":"2024","unstructured":"Zhi Y, Wang Q, Zi M et al (2024) Spatial transcriptomic and metabolomic landscapes of oral submucous fibrosis-derived oral squamous cell carcinoma and its tumor microenvironment. Adv Sci (Weinh) 11(12):e2306515","journal-title":"Adv Sci (Weinh)"},{"issue":"24","key":"5732_CR25","doi-asserted-by":"publisher","first-page":"22156","DOI":"10.1002\/cam4.6735","volume":"12","author":"S Jin","year":"2023","unstructured":"Jin S, Tsunematsu T, Horiguchi T et al (2023) Involvement of the OTUB1-YAP1 axis in driving malignant behaviors of head and neck squamous cell carcinoma. Cancer Med 12(24):22156\u201322169","journal-title":"Cancer Med"},{"key":"5732_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5759927","author":"L Xu","year":"2021","unstructured":"Xu L, Li YY, Zhang YC et al (2021) A novel ferroptosis-related gene signature to predict prognosis in patients with head and neck squamous cell carcinoma. Dis Markers. https:\/\/doi.org\/10.1155\/2021\/5759927","journal-title":"Dis Markers"},{"key":"5732_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110835","volume":"110","author":"Y Li","year":"2023","unstructured":"Li Y, Li R, Qin H et al (2023) OTUB1\u2019s role in promoting OSCC development by stabilizing RACK1 involves cell proliferation, migration, invasion, and tumor-associated macrophage M1 polarization. Cell Signal 110:110835","journal-title":"Cell Signal"},{"key":"5732_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111747","author":"M Mani","year":"2025","unstructured":"Mani M, Park JW, Martin TFJ (2025) Regulatory mechanisms and therapeutic targeting of PD-L1 trafficking and stability in cancer immunotherapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17111747","journal-title":"Cancers (Basel)"},{"key":"5732_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.canlet.2021.12.002","volume":"526","author":"Y Liao","year":"2022","unstructured":"Liao Y, Yang M, Wang K et al (2022) Deubiquitinating enzyme OTUB1 in immunity and cancer: good player or bad actor? Cancer Lett 526:248\u2013258","journal-title":"Cancer Lett"},{"key":"5732_CR30","doi-asserted-by":"crossref","unstructured":"Zhang Z, Sun D, Tang H et al (2023) PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK\/NF-kappaB pathway and PD-L1 expression. J Immunother Cancer. ;11(11)","DOI":"10.1136\/jitc-2023-007627"},{"issue":"1","key":"5732_CR31","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"WT Ju","year":"2022","unstructured":"Ju WT, Xia RH, Zhu DW et al (2022) A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun 13(1):5378","journal-title":"Nat Commun"},{"issue":"1","key":"5732_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00795-020-00270-6","volume":"54","author":"N Akisada","year":"2021","unstructured":"Akisada N, Nishimoto K, Takao S et al (2021) Correction to: PD-L1 expression in tongue squamous cell carcinoma. Med Mol Morphol 54(1):68","journal-title":"Med Mol Morphol"},{"issue":"10","key":"5732_CR33","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.ymthe.2020.06.024","volume":"28","author":"L Liu","year":"2020","unstructured":"Liu L, Wu Y, Li Q et al (2020) METTL3 promotes tumorigenesis and metastasis through BMI1 m(6)A methylation in oral squamous cell carcinoma. Mol Ther 28(10):2177\u20132190","journal-title":"Mol Ther"},{"issue":"1","key":"5732_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12935-022-02715-7","volume":"22","author":"J Chen","year":"2022","unstructured":"Chen J, Li S, Huang Z et al (2022) METTL3 suppresses anlotinib sensitivity by regulating m(6)A modification of FGFR3 in oral squamous cell carcinoma. Cancer Cell Int 22(1):295","journal-title":"Cancer Cell Int"},{"key":"5732_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6149558","volume":"2021","author":"Y Ai","year":"2021","unstructured":"Ai Y, Liu S, Luo H et al (2021) METTL3 intensifies the progress of oral squamous cell carcinoma via modulating the m6A amount of PRMT5 and PD-L1. J Immunol Res 2021:6149558","journal-title":"J Immunol Res"},{"issue":"6","key":"5732_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco AG, Chen R, Worden FP et al (2021) Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 22(6):883\u2013892","journal-title":"Lancet Oncol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05732-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05732-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:22Z","timestamp":1792569322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05732-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5732"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05732-6","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was ratified by the Ethics Committee of Longyan First Affiliated Hospital of Fujian Medical University and strictly adhered to the ethical principles outlined in the Declaration of Helsinki. All patients signed written informed consent forms for their tissue samples to be used for scientific research. All animal experiments were ratified by the Animal Ethics Committee of Longyan First Affiliated Hospital of Fujian Medical University. The animal experiments have been carried out in accordance with the ARRIVE guidelines.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}